IRADIMED CORP (IRMD) Fundamental Analysis & Valuation

NASDAQ:IRMD • US46266A1097

99.77 USD
+0.83 (+0.84%)
Last: Mar 11, 2026, 01:57 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IRMD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

8

Overall IRMD gets a fundamental rating of 8 out of 10. We evaluated IRMD against 184 industry peers in the Health Care Equipment & Supplies industry. IRMD has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IRMD is not priced too expensively while it is growing strongly. Keep and eye on this one! These ratings could make IRMD a good candidate for growth and quality investing.


Dividend Valuation Growth Profitability Health

9

1. IRMD Profitability Analysis

1.1 Basic Checks

  • IRMD had positive earnings in the past year.
  • In the past year IRMD had a positive cash flow from operations.
  • IRMD had positive earnings in each of the past 5 years.
  • Of the past 5 years IRMD 4 years had a positive operating cash flow.
IRMD Yearly Net Income VS EBIT VS OCF VS FCFIRMD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5M 10M 15M 20M 25M

1.2 Ratios

  • IRMD has a Return On Assets of 18.47%. This is amongst the best in the industry. IRMD outperforms 98.37% of its industry peers.
  • IRMD's Return On Equity of 21.54% is amongst the best of the industry. IRMD outperforms 95.65% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 19.32%, IRMD belongs to the top of the industry, outperforming 97.28% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for IRMD is significantly above the industry average of 9.15%.
Industry RankSector Rank
ROA 18.47%
ROE 21.54%
ROIC 19.32%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
IRMD Yearly ROA, ROE, ROICIRMD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 10 15 20 25

1.3 Margins

  • IRMD has a Profit Margin of 26.31%. This is amongst the best in the industry. IRMD outperforms 96.74% of its industry peers.
  • IRMD's Profit Margin has improved in the last couple of years.
  • IRMD has a better Operating Margin (30.87%) than 98.37% of its industry peers.
  • IRMD's Operating Margin has improved in the last couple of years.
  • IRMD has a Gross Margin of 77.07%. This is amongst the best in the industry. IRMD outperforms 88.59% of its industry peers.
  • IRMD's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 30.87%
PM (TTM) 26.31%
GM 77.07%
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
IRMD Yearly Profit, Operating, Gross MarginsIRMD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. IRMD Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so IRMD is creating value.
  • The number of shares outstanding for IRMD remains at a similar level compared to 1 year ago.
  • IRMD has more shares outstanding than it did 5 years ago.
  • There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
IRMD Yearly Shares OutstandingIRMD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
IRMD Yearly Total Debt VS Total AssetsIRMD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 49.11 indicates that IRMD is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of IRMD (49.11) is better than 99.46% of its industry peers.
  • There is no outstanding debt for IRMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 49.11
ROIC/WACC1.96
WACC9.87%
IRMD Yearly LT Debt VS Equity VS FCFIRMD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.3 Liquidity

  • IRMD has a Current Ratio of 6.64. This indicates that IRMD is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 6.64, IRMD belongs to the best of the industry, outperforming 83.70% of the companies in the same industry.
  • A Quick Ratio of 5.72 indicates that IRMD has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 5.72, IRMD belongs to the best of the industry, outperforming 84.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.64
Quick Ratio 5.72
IRMD Yearly Current Assets VS Current LiabilitesIRMD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. IRMD Growth Analysis

3.1 Past

  • IRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.36%, which is quite good.
  • IRMD shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 36.18% yearly.
  • Looking at the last year, IRMD shows a quite strong growth in Revenue. The Revenue has grown by 14.43% in the last year.
  • The Revenue has been growing by 21.45% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%

3.2 Future

  • The Earnings Per Share is expected to grow by 11.02% on average over the next years. This is quite good.
  • Based on estimates for the next years, IRMD will show a quite strong growth in Revenue. The Revenue will grow by 10.59% on average per year.
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
IRMD Yearly Revenue VS EstimatesIRMD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M 100M
IRMD Yearly EPS VS EstimatesIRMD Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. IRMD Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 51.96, the valuation of IRMD can be described as expensive.
  • Compared to the rest of the industry, the Price/Earnings ratio of IRMD indicates a somewhat cheap valuation: IRMD is cheaper than 66.30% of the companies listed in the same industry.
  • IRMD is valuated expensively when we compare the Price/Earnings ratio to 26.25, which is the current average of the S&P500 Index.
  • IRMD is valuated quite expensively with a Price/Forward Earnings ratio of 47.03.
  • IRMD's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. IRMD is cheaper than 67.93% of the companies in the same industry.
  • When comparing the Price/Forward Earnings ratio of IRMD to the average of the S&P500 Index (24.39), we can say IRMD is valued expensively.
Industry RankSector Rank
PE 51.96
Fwd PE 47.03
IRMD Price Earnings VS Forward Price EarningsIRMD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 65.22% of the companies in the same industry are more expensive than IRMD, based on the Enterprise Value to EBITDA ratio.
  • 70.11% of the companies in the same industry are more expensive than IRMD, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 90.97
EV/EBITDA 46.53
IRMD Per share dataIRMD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IRMD does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of IRMD may justify a higher PE ratio.
PEG (NY)4.95
PEG (5Y)1.44
EPS Next 2Y11.02%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

3

5. IRMD Dividend Analysis

5.1 Amount

  • With a yearly dividend of 0.71%, IRMD is not a good candidate for dividend investing.
  • IRMD's Dividend Yield is rather good when compared to the industry average which is at 0.21. IRMD pays more dividend than 91.30% of the companies in the same industry.
  • With a Dividend Yield of 0.71, IRMD pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.71%

5.2 History

  • IRMD has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
IRMD Yearly Dividends per shareIRMD Yearly Dividends per shareYearly Dividends per share 2022 2023 2024 2025 2026 0.5 1 1.5

5.3 Sustainability

  • 39.59% of the earnings are spent on dividend by IRMD. This is a low number and sustainable payout ratio.
DP39.59%
EPS Next 2Y11.02%
EPS Next 3YN/A
IRMD Yearly Income VS Free CF VS DividendIRMD Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
IRMD Dividend Payout.IRMD Dividend Payout, showing the Payout Ratio.IRMD Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IRMD Fundamentals: All Metrics, Ratios and Statistics

IRADIMED CORP

NASDAQ:IRMD (3/11/2026, 1:57:59 PM)

99.77

+0.83 (+0.84%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-04
Inst Owners60.49%
Inst Owner Change3.31%
Ins Owners36.78%
Ins Owner Change-0.61%
Market Cap1.27B
Revenue(TTM)83.81M
Net Income(TTM)21.18M
Analysts82.5
Price Target122.4 (22.68%)
Short Float %5.92%
Short Ratio6.4
Dividend
Industry RankSector Rank
Dividend Yield 0.71%
Yearly Dividend1.08
Dividend Growth(5Y)N/A
DP39.59%
Div Incr Years0
Div Non Decr Years0
Ex-Date02-23
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.85%
Min EPS beat(2)1.27%
Max EPS beat(2)10.44%
EPS beat(4)3
Avg EPS beat(4)2.54%
Min EPS beat(4)-1.96%
Max EPS beat(4)10.44%
EPS beat(8)6
Avg EPS beat(8)4.28%
EPS beat(12)10
Avg EPS beat(12)6.04%
EPS beat(16)14
Avg EPS beat(16)9.77%
Revenue beat(2)2
Avg Revenue beat(2)0.71%
Min Revenue beat(2)0.01%
Max Revenue beat(2)1.41%
Revenue beat(4)2
Avg Revenue beat(4)-0.08%
Min Revenue beat(4)-1.05%
Max Revenue beat(4)1.41%
Revenue beat(8)3
Avg Revenue beat(8)-0.25%
Revenue beat(12)6
Avg Revenue beat(12)-0.02%
Revenue beat(16)7
Avg Revenue beat(16)-0.16%
PT rev (1m)21.21%
PT rev (3m)21.21%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-1.89%
EPS NY rev (3m)-1.89%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)1.02%
Revenue NY rev (3m)1.02%
Valuation
Industry RankSector Rank
PE 51.96
Fwd PE 47.03
P/S 15.76
P/FCF 90.97
P/OCF 50.74
P/B 12.9
P/tB 13.36
EV/EBITDA 46.53
EPS(TTM)1.92
EY1.92%
EPS(NY)2.12
Fwd EY2.13%
FCF(TTM)1.1
FCFY1.1%
OCF(TTM)1.97
OCFY1.97%
SpS6.33
BVpS7.73
TBVpS7.47
PEG (NY)4.95
PEG (5Y)1.44
Graham Number18.28
Profitability
Industry RankSector Rank
ROA 18.47%
ROE 21.54%
ROCE 24.38%
ROIC 19.32%
ROICexc 43.38%
ROICexgc 46.87%
OM 30.87%
PM (TTM) 26.31%
GM 77.07%
FCFM 17.33%
ROA(3y)19.63%
ROA(5y)17.03%
ROE(3y)23.33%
ROE(5y)20.07%
ROIC(3y)20.45%
ROIC(5y)17.53%
ROICexc(3y)50.3%
ROICexc(5y)54.7%
ROICexgc(3y)53.86%
ROICexgc(5y)59.46%
ROCE(3y)25.8%
ROCE(5y)22.12%
ROICexgc growth 3Y-15.8%
ROICexgc growth 5YN/A
ROICexc growth 3Y-12.49%
ROICexc growth 5YN/A
OM growth 3Y2.08%
OM growth 5YN/A
PM growth 3Y3.67%
PM growth 5Y44.08%
GM growth 3Y-0.3%
GM growth 5Y0.65%
F-Score4
Asset Turnover0.7
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 1128.47%
Cap/Sales 13.74%
Interest Coverage 250
Cash Conversion 96.82%
Profit Quality 65.85%
Current Ratio 6.64
Quick Ratio 5.72
Altman-Z 49.11
F-Score4
WACC9.87%
ROIC/WACC1.96
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.36%
EPS 3Y20.77%
EPS 5Y36.18%
EPS Q2Q%22.73%
EPS Next Y10.5%
EPS Next 2Y11.02%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)14.43%
Revenue growth 3Y16.29%
Revenue growth 5Y21.45%
Sales Q2Q%17.03%
Revenue Next Year11.27%
Revenue Next 2Y10.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.55%
EBIT growth 3Y18.71%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-18.68%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.2%
OCF growth 3YN/A
OCF growth 5YN/A

IRADIMED CORP / IRMD FAQ

Can you provide the ChartMill fundamental rating for IRADIMED CORP?

ChartMill assigns a fundamental rating of 8 / 10 to IRMD.


Can you provide the valuation status for IRADIMED CORP?

ChartMill assigns a valuation rating of 4 / 10 to IRADIMED CORP (IRMD). This can be considered as Fairly Valued.


Can you provide the profitability details for IRADIMED CORP?

IRADIMED CORP (IRMD) has a profitability rating of 9 / 10.


What are the PE and PB ratios of IRADIMED CORP (IRMD) stock?

The Price/Earnings (PE) ratio for IRADIMED CORP (IRMD) is 51.96 and the Price/Book (PB) ratio is 12.9.


Can you provide the financial health for IRMD stock?

The financial health rating of IRADIMED CORP (IRMD) is 9 / 10.